Influence of EMAP II, IFN-α2b and its medicinal preparations on the MGMT protein amount in human cells in vitro

Kotsarenko, K. V.; Lylo, V. V.; Ruban, T. P.; Macewicz, L. L.; Kornelyuk, A. I.; Chernykh, S. I.; Lukash, L. L.

doi:10.7124/bc.0008BF

Biopolym. Cell. 2014; 30(6):448-453.

http://dx.doi.org/10.7124/bc.0008BF

Genomics, Transcriptomics and Proteomics

Influence of EMAP II, IFN-α2b and its medicinal preparations on the MGMT protein amount in human cells in vitro

1Kotsarenko K. V., 1Lylo V. V., 1Ruban T. P., 1Macewicz L. L., 1Kornelyuk A. I., 1Chernykh S. I., 1Lukash L. L.

Institute of Molecular Biology and Genetics, NAS of Ukraine
150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680

Abstract

Aim. To study the effect of EMAP II, IFN-α2b and its medicinal preparations on the amount of O⁶-methylguanine-DNA methyltransferase (MGMT) protein in human cells in vitro. Methods. The human cells of 4BL and Hep-2 lines were treated with the purified recombinant proteins EMAP II, IFN-α2b and its commercial me dicinal preparations. Changes in the MGMT gene expression were studied at a protein level by Western blot analysis. Results. Treatment of Hep-2 and 4BL cells with EMAP II at the concentrations of 0.02 mg/ml and 2 mg/ml respectively led to induction of the MGMT gene expression. EMAP II at the concentrations of 0.2–20 g/ml caused decrease of the MGMT protein amount in Hep-2 cells. The regulating activity of EMAP II was also observed for MARP (anti-Methyltransferase Antibody Recognizable Protein). IFN-α2b and Laferon-PharmBiotek with the activity of 200 and 2000 IU/ml were shown to cause an increase of the MGMT protein amount in Hep-2 cells. Conclusions. The purified recombinant proteins EMAP II and IFN-α2b which are substrates for the medicinal preparations influenced on the amount of MGMT protein in the human cell cultures in a concentration-dependent manner. At the same time the effect of medicinal preparations differs from that of the purified protein IFN-α2b. Possibly it depends on the presence of stabilizing components in their compositions.

Keywords: MGMT, MARP, IFN-α2b, EMAP II, human cell cultures

Full text: (PDF, in English)

References

[1] Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307.

[2] Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007;6(8):1079-99.

[3] Turriziani M, Caporaso P, Bonmassar L, Buccisano F, Amadori S, Venditti A, Cantonetti M, D'Atri S, Bonmassar E. O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res. 2006;53(4):317-23.

[4] Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005;65(17):7573-9.

[5] Rosati SF, Williams RF, Nunnally LC, McGee MC, Sims TL, Tracey L, Zhou J, Fan M, Ng CY, Nathwani AC, Stewart CF, Pfeffer LM, Davidoff AM. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol Cancer Ther. 2008;7(12):3852-8.

[6] Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008;7(12):3842-51.

[7] Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T. Benefits of interferon-? and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 2011;117(8):1721-30.

[8] Olson JJ, McKenzie E, Skurski-Martin M, Zhang Z, Brat D, Phuphanich S. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol. 2008;90(3):293-9.

[9] Ivakhno SS, Kornelyuk AI. Cytokine-like activities of some aminoacyl-tRNA synthetases and auxiliary p43 cofactor of aminoacylation reaction and their role in oncogenesis. Exp Oncol. 2004;26(4):250-5.

[10] Schwarz RE, Schwarz MA. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. J Surg Res. 2004;120(1):64-72.

[11] Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. Ann Surg Oncol. 2010;17(5):1442-52.

[12] Kotsarenko KV, Lylo VV, Macewicz LL, Babenko LA, Kornelyuk AI, Ruban TA, et al. Change in the MGMT gene expression under the influence of exogenous cytokines in human cells in vitro. Cytol Genet. 2013;47(4):202–9.

[13] Lylo VV, Karpova IS, Kotsarenko KV, Matsevych LL, Ruban TO, Lukash LL. Lectins of Sambucus nigra in regulation of cellular DNA-protective mechanisms. First Int. Symp. on Elderberry (Columbia, june 9-14, 2013). Columbia, 2013; 27.

[14] Pegg AE, Fang Q, Loktionova NA. Human variants of O6-alkylguanine-DNA alkyltransferase. DNA Repair (Amst). 2007;6(8):1071-8.

[15] Lylo VV, Matsevich LL, Kotsarenko EV, Babenko LA, Kornelyuk AI, Sukhorada EM, et al. Activation of gene expression of the O6-methylguanine-DNA-transferase repair enzyme upon the influence of EMAP II cytokine in human cells in vitro. Cytol Genet. 2011;45(6):373–8.

[16] Lukash LL, Iatsyshyna AP, Kushniruk VO, Pidpala OV. Reprogramming of somatic cells of adults in vitro. Topics in experimental evolution of organisms. Kyiv, Logos, 2011; 11:493-8.

[17] Vozianov AF, Reznikov AG, Kornelyuk AI, Romanenko AM, Chaikovskaya LV, Polyakova LI, Grigorenko VN. Effects of recombinant protein EMAP II on the growth, histological and histochemical features of the heterotransplants of human prostate cancer. Journal of Academy of Medical Sciences of Ukraine. 2008; 14(4):719-30.

[18] Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI, Grygorenko VN. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts. Exp Oncol. 2011;33(4):231-4.

[19] Dubrovsky AL, Brown Jn, Kornelyuk AI, Murray JC, Matsuka GKh. Bacterial expression of full-length and truncated forms of cytokine EMAP-2 and cytokine-like domain of mammalian tyrosyl-tRNA synthetase. Biopolym Cell. 2000; 16(3):229-35.

[20] Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. Exp Oncol. 2007;29(4):267-71.

[21] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.

[22] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.

[23] Green MR, Sambrook J. Molecular Cloning: A Laboratory Manual 4th edition Cold Spring Harbor Laboratory Press. 2012; 2028 p.

[24] Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ. The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods. 2008;172(2):250-4.

[25] Macewicz LL, Kushniruk VO, Iatsyshyna AP, Kotsarenko KV, Lylo VV, Akopyan GR, Huleuk NL, Mykytenko DO, Lukash LL. Correlation of mutagenesis level with expression of reparative enzyme O6-methylguanine DNA methyltransferase during establishment of cell lines in vitro. Biopolym Cell. 2013; 29(6):480-6.

[26] Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res. 2007;67(18):8952-9.

[27] Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275-306.

[28] Li Z, Liu YH, Xue YX, Liu LB, Wang P. Low-dose endothelial monocyte-activating polypeptide-ii increases permeability of blood-tumor barrier by caveolae-mediated transcellular pathway. J Mol Neurosci. 2014;52(3):313-22.

[29] Park SG, Kang YS, Ahn YH, Lee SH, Kim KR, Kim KW, Koh GY, Ko YG, Kim S. Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. J Biol Chem. 2002;277(47):45243-8.

[30] Boldogh I, Ramana CV, Chen Z, Biswas T, Hazra TK, Gr?sch S, Grombacher T, Mitra S, Kaina B. Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Cancer Res. 1998;58(17):3950-6.

[31] Ko YG, Park H, Kim T, Lee JW, Park SG, Seol W, Kim JE, Lee WH, Kim SH, Park JE, Kim S. A cofactor of tRNA synthetase, p43, is secreted to up-regulate proinflammatory genes. J Biol Chem. 2001;276(25):23028-33.